A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This study consists of dose escalation evaluation to determine the safety and tolerability of
ADA-011 as a monotherapy and in combination with a checkpoint inhibitor. Following dose
escalation, one or more dose expansion cohorts in selected indications will be explored to
further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.